VEGFA and neoplasm: Studies have shown that this drug causes a decrease in the normal cells’ production of the proinflammatory chemokine (C-C motif) ligand 2 (CCL2), which recruits monocytes to the tumor sites, and a decrease of interleukin-6 (a growth factor implicated in several malignancies), and VEGF.